Falkenberg K, et al. - In view of the observation that in healthy volunteers, calcitonin gene-related peptide (CGRP) induces a mild headache and in migraine patients, it induces migraine-like headache, it is expected that the induced headache must respond to already established migraine treatment for validation. Hence researchers here examined the effect of sumatriptan against CGRP-induced symptoms in an effort to authenticate CGRP-induced headache as a model for drug testing. They assigned 30 healthy volunteers to receive a 2-hour infusion of CGRP on 2 separate days. Pretreatment with sumatriptan 1 day and with placebo the other day was provided to the participants in this randomized double-blind cross-over fashion. On the sumatriptan day, CGRP-induced headache in 86% (25/29) of the participants and on the placebo day, the headache was induced in 96% (28/29) of the participants. Outcomes revealed no influence of sumatriptan on CGRP induced headache score, accompanying symptoms or other symptoms. Besides, a wide range of side effects was seen with a 2-hour CGRP infusion and the 2-hour CGRP infusion does not induce more headache than the usual 20-minute infusion. Thus, they did not identify the prolonged infusion of CGRP in healthy volunteers as a valid and pragmatic model for inquiring new anti-migraine drugs.